69
Views
28
CrossRef citations to date
0
Altmetric
Review

p38 Inhibitors: beyond pyridinylimidazoles

, &
Pages 801-816 | Published online: 13 Jul 2005
 

Abstract

Since the discovery of p38 mitogen-activated protein kinase (MAPK) as a potential intracellular modulator that regulates the crucial biosynthesis and functions of pro-inflammatory cytokines (e.g., TNF-α and IL-1β), numerous groups have disclosed their efforts to find small-molecule p38 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases such as rheumatoid arthritis (RA), Crohn’s disease (CD) and psoriasis. Although greater selectivity has been achieved with these newly disclosed series, their safety profile after chronic treatment remains a question to be answered in human clinical trials. The p38 inhibitors that have been disclosed in the recent patent literature (2000 – 2004) are summarised here. These compounds will be classified into series based on their intrinsic structures and by their binding modes, as revealed by either crystallography or molecular modelling.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.